Testing the addition of an anti-cancer drug, vorasidenib, to the usual treatment, temozolomide, after radiation therapy for advanced brain cancer

Full Title

Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas (A072301) (CIRB)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Lauren Schaff’s office at 212-610-0485.